AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Elahere (mirvetuximab soravtansine) by Year
Elahere (mirvetuximab soravtansine) — International net revenues ($M) ($M)
AbbVie Elahere (mirvetuximab soravtansine): $83M in FY2025, up 4,050.0% from a year earlier.
Latest, FY2025
83
Period ended Dec 31, 2025
Change on a year earlier
+4,050.0%
2 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Elahere (mirvetuximab soravtansine) — International net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 83 | +4,050.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 2 | – | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-14) ↗ |
Cite this data
StockData. (2026). AbbVie Elahere (mirvetuximab soravtansine) ($M), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/elahere-intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.